KRAS and neoplasm: The plasma/tumor-matched mutations included 4 TP53 mutations (H193Y, Y205C, Y234N, and R248W), 2 KRAS mutations (G12D and G13D), 2 APC mutations (R216* and E1306*), one PIK3CA mutation (E545K), 2 EGFR mutations (A611T and R831H), and one nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) mutation (R34G).